School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China; Department of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, Affiliated Dongguan Hospital, Southern Medical University, Dongguan 523018, China.
School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China.
J Control Release. 2022 Oct;350:525-537. doi: 10.1016/j.jconrel.2022.08.050. Epub 2022 Sep 1.
To overcome drug resistance and improve precision theranostics for hepatocellular carcinoma (HCC), a nanoplatform with an "off/on" function for multimodality imaging (near-infrared-II (NIR-II) fluorescence imaging, magnetic resonance imaging (MRI), and photoacoustic imaging) and synergistic therapy (photodynamic therapy and ferroptosis) activated by an acidic pH in the tumor microenvironment is proposed. Although many photosensitizers with photodynamic effects have been reported, very few of them have outstanding photodynamic effect and high stability with response to endogenous stimuli capable of NIR-II imaging. Herein, a new amphiphilic photosensitizer SR780 derived from croconaine dye, was developed with satisfactory photodynamic effects and pH-responsive NIR-II imaging. Interestingly, it was deactivated by coordination with Fe (SR780@Fe) and activated during their release under mild acidic condition. Ferroptosis can generate hydroxyl free radical and lipid peroxide, which aggravate the oxidative stress of tumor cells and mediate their death while depleting glutathione (GSH) to enhance photodynamic effect. In situ pH-activatable theranostic nanoplatform, SR780@Fe-PAE-GP, was thus developed by loading SR780@Fe with pH-responsive polymers, modified by a glypican-3 (GPC-3) receptor-targeting peptide. The synergistic antitumor effects were confirmed both in vitro and in vivo, and the tumor inhibition rate of the SR780@Fe-PAE-GP + L treatment group reached 98%.
为了克服肝癌(HCC)的耐药性并提高精准治疗水平,提出了一种具有肿瘤微环境中酸性 pH 值触发的“开/关”功能的多功能成像(近红外-II(NIR-II)荧光成像、磁共振成像(MRI)和光声成像)和协同治疗(光动力治疗和铁死亡)的纳米平台。尽管已经报道了许多具有光动力效应的光敏剂,但很少有具有出色光动力效应和对能够进行 NIR-II 成像的内源性刺激有响应的高稳定性的光敏剂。在此,开发了一种新型两亲性光敏剂 SR780,它源自 Croconaine 染料,具有令人满意的光动力效应和 pH 响应的 NIR-II 成像。有趣的是,它通过与 Fe 的配位(SR780@Fe)而失活,并在温和酸性条件下释放时被激活。铁死亡会产生羟基自由基和脂质过氧化物,从而加剧肿瘤细胞的氧化应激并介导其死亡,同时耗竭谷胱甘肽(GSH)以增强光动力效应。因此,通过将 SR780@Fe 与 pH 响应聚合物装载,并修饰具有 GPC-3 受体靶向肽,开发了原位 pH 激活治疗性纳米平台 SR780@Fe-PAE-GP。在体外和体内均证实了协同抗肿瘤作用,SR780@Fe-PAE-GP+L 治疗组的肿瘤抑制率达到 98%。
J Control Release. 2022-10
ACS Appl Mater Interfaces. 2021-4-21
Mater Today Bio. 2025-7-3
Int J Nanomedicine. 2025-5-29
Int J Nanomedicine. 2024